KRT20
Reactivité: Humain, Souris, Rat
WB, IHC (p), IF (cc)
Hôte: Lapin
Monoclonal
1F10
unconjugated
Indications d'application
Optimal dilution of the CK20 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
Restrictions
For Research Use only
Format
Liquid
Buffer
Prediluted in 1X PBS, 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide, *For IHC use only*
Agent conservateur
Sodium azide
Précaution d'utilisation
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Stock
4 °C,-20 °C
Stockage commentaire
Store the CK20 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Antigène
KRT20
(Keratin 20 (KRT20))
Autre désignation
CK20
Sujet
This mAb recognizes an intermediate filament protein of 46 kDa, identified as Cytokeratin 20 (KRT20, CK20). KRT is abundantly expressed in goblet cells and enterocytes of the gastrointestinal tract. It is a useful marker of pancreatic and colorectal cancer. KRT20 is expressed under normal, hyperplastic and neoplastic conditions. It has been detected in adenocarcinomas of the colon, stomach and biliary tract. Breast carcinomas are generally non-reactive.